Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM study of vesleteplirsen in Duchenne muscular dystrophy amenable to exon 51 skipping
NL-OMON58675Phase 2Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Jul 2022
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Vesleteplirsen in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Sarepta Therapeutics. Primary endpoints: Incidence of adverse events and Change from baseline in dystrophin protein level. Started Jul 2022; status: completed.
02
Drugs
Vesleteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON58675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58675.